ZBIO
Zenas BioPharma, Inc.
28.70
+0.12 (+0.42%)
52w low 13.50
44.60 high
48.9% of range
Financial Analysis
| Ratio | Jun 25 | Sep 25 | Dec 25 | Mar 26 | Jun 26 | Sep 26 | Trend |
|---|---|---|---|---|---|---|---|
| Profitability | |||||||
| Operating Margin | -- | -- | -- | -- | -7,765.9% | -759.1% | |
| EBITDA Margin | -- | -- | -- | -- | -10,103.6% | -976.5% | |
| Net Margin | -- | -- | -- | -- | -11,145.6% | -1,089.2% | |
| FCF Margin | -- | -- | -- | -- | -8,723.7% | -279.9% | |
| Returns | |||||||
| Return on Equity | -- | -26.2% | -99.3% | -24.1% | -45.1% | -51.0% | |
| Return on Assets | -- | -16.0% | -62.7% | -10.8% | -15.9% | -16.1% | |
| Return on Inv Capital | -- | -25.4% | -95.2% | -12.4% | -18.6% | -45.5% | |
| Liquidity | |||||||
| Current Ratio | -- | 5.66x | 5.61x | 11.94x | 9.93x | 9.42x | |
| Quick Ratio | -- | 5.66x | 5.61x | 11.94x | 9.93x | 9.42x | |
| Cash Ratio | -- | 2.20x | 1.77x | 8.18x | 2.99x | 2.78x | |
| Leverage | |||||||
| Debt / Equity | -- | 0.00x | 0.01x | 0.79x | 1.21x | 0.01x | |
| Net Debt / EBITDA | -- | -- | -- | -- | -0.99x | -- | |
| Interest Coverage | -- | -29.67x | -- | -11.21x | -9.81x | -8.70x | |
| Equity Multiplier | -- | 1.64x | 1.58x | 2.23x | 2.84x | 3.16x | |
| Efficiency | |||||||
| Asset Turnover | -- | 0.00x | 0.00x | 0.00x | 0.00x | 0.01x | |
| Effective Tax Rate | -- | -0.0% | -0.0% | -0.0% | -0.1% | -0.0% | |
| Op CF / Net Income | -- | 0.80x | 0.22x | 0.93x | 0.51x | 0.53x | |
| Investment | |||||||
| Capex / Revenue | -- | -- | -- | -- | 3,000.0% | 0.0% | |
| R&D / Revenue | -- | -- | -- | -- | 6,291.3% | 584.7% | |
| SG&A / Revenue | -- | -- | -- | -- | 1,574.6% | 274.4% | |
Revenue CAGR
--
Net Income CAGR
--
EPS CAGR
--
FCF CAGR
--
Revenue YoY
+900.0%